120 related articles for article (PubMed ID: 38780897)
1. Crizotinib enhances PARP inhibitor efficacy in ovarian cancer cells and xenograft models by inducing autophagy.
Santiago-O'Farrill JM; Blessing Bollu A; Yang H; Orellana V; Pina M; Zhang X; Liu J; Bast RC; Lu Z
Mol Cancer Res; 2024 May; ():. PubMed ID: 38780897
[TBL] [Abstract][Full Text] [Related]
2. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
3. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
[TBL] [Abstract][Full Text] [Related]
4. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.
Blessing AM; Santiago-O'Farrill JM; Mao W; Pang L; Ning J; Pak D; Bollu LR; Rask P; Iles L; Yang H; Tran S; Elmir E; Bartholomeusz G; Langley R; Lu Z; Bast RC
Cancer; 2020 Aug; 126(15):3579-3592. PubMed ID: 32484926
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
7. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
8. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
9. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
[TBL] [Abstract][Full Text] [Related]
10. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
11. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Shim JI; Ryu JY; Jeong SY; Cho YJ; Choi JJ; Hwang JR; Choi JY; Sa JK; Lee JW
Gynecol Oncol; 2022 May; 165(2):270-280. PubMed ID: 35305818
[TBL] [Abstract][Full Text] [Related]
12. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
13. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662
[TBL] [Abstract][Full Text] [Related]
14. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
16. Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance.
Uddin MH; Zhou JY; Pimentel J; Patrick SM; Kim S; Shekhar MP; Wu GS
Front Oncol; 2022; 12():908603. PubMed ID: 35847859
[TBL] [Abstract][Full Text] [Related]
17. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.
Sahin ID; Jönsson JM; Hedenfalk I
Oncotarget; 2019 Dec; 10(65):6981-6996. PubMed ID: 31857852
[TBL] [Abstract][Full Text] [Related]
19. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
